Elicio Therapeutics (ELTX) Payables (2020 - 2026)
Elicio Therapeutics posted quarterly Payables of $272000.0 for Q1 2026, down 93.26% year-on-year from $4.0 million in Q1 2025, and down 59.52% on a QoQ basis from $672000.0 in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Payables data on file, last reported at $272000.0 in Q1 2026.
- For the quarter ending Q1 2026, Payables fell 93.26% year-over-year to $272000.0; the trailing twelve-month figure through Mar 2026 stood at $272000.0 (down 93.26% YoY), and the FY2025 full-year result was $672000.0, down 35.26% from the prior year.
- Payables for Q1 2026 stood at $272000.0, down from $672000.0 in the prior quarter.
- Across five years, Payables topped out at $4.4 million in Q3 2023 and bottomed at $272000.0 in Q1 2026.
- The 5-year median for Payables is $2.2 million (2022), against an average of $2.3 million.
- The widest annual swing landed in 2025, when Payables jumped 266.35%; it then plunged 93.26% in 2026.
- A 5-year view of Payables shows it stood at $2.8 million in 2022, then surged by 55.76% to $4.4 million in 2023, then tumbled by 76.24% to $1.0 million in 2024, then slumped by 35.26% to $672000.0 in 2025, then slumped by 59.52% to $272000.0 in 2026.
- The last three Payables figures came in at $272000.0 (Q1 2026), $672000.0 (Q4 2025), and $321000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | 272,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 272,000.00 |
| Dec 31, 2025 | 672,000.00 |
| Sep 30, 2025 | 321,000.00 |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 4.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.06 Mn |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 4.41 Mn |
| Jun 30, 2023 | 4.27 Mn |
| Mar 31, 2023 | 692,000.00 |
| Dec 31, 2022 | 2.81 Mn |
| Sep 30, 2022 | 2.22 Mn |
| Jun 30, 2022 | 2.66 Mn |
| Mar 31, 2022 | 3.43 Mn |
| Dec 31, 2021 | 4.71 Mn |
| Sep 30, 2021 | 7.68 Mn |
| Jun 30, 2021 | 9.31 Mn |
| Mar 31, 2021 | 6.69 Mn |
| Dec 31, 2020 | 56.75 Mn |